Considerations on the clinical application of the human papillomavirus vaccine in Spain

Human Vaccines

Volumn 7, Issue 5, 2011, Pages 585-589

  Cortés, Javier ^a   Martinon Torres, Federico ^b   Ramón Y Cajal, José Manuel ^c   Ferret, Gabriel ^d   Gil, Angel ^e  

^a Policlínica Miramar ^*  (Spain)

^b Research Institute of Santiago de Compostela ^*  (Spain)

^c Santiago University Clinical Hospital   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

^e UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Barriers; Coverage; Human papillomavirus; Vaccine; Vaccine implementation

Indexed keywords

WART VIRUS VACCINE;

ATTITUDE TO HEALTH; CANCER PREVENTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; NOTE; REVACCINATION; SPAIN; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH POLICY; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; SPAIN; VACCINATION; YOUNG ADULT;

EID: 79955952978     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.5.14817     Document Type: Note

References (40)

1. Cortes J, Bosch X, Martinón F, Morillo C. III Foro Español sobre Virus de Papiloma Humano. Valencia 24 de Septiembre de 2010; Madrid (Spain): SPMSD Eds.; In press.
2. Cervarix® - EPAR. Available at: www.emea.europa.eu/humandocs/PDFs/ EPAR/cervarix/H-721-PI-es.pdf (last access dec-2010).
3. Gardasil® - EPAR Available at:: www.emea.europa.eu/humandocs/PDFs/ EPAR/gardasil/H-703-PI-es.pdf (last access dec-2010).
4. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine uptake among women aged 19-26: Importance of a physician's recommendation. Vaccine 2010; [Epub ahead of print]; PMID: 20056186.
5. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23:569-78. (Pubitemid 39473185)
6. Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009; 27:337-47.
7. th International Papillomavirus conference, Montreal 3-8 july 2010; (P689). Available at www.hpv2010.com (last accessed dec 2010).
8. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2:868-79.
9. th International Papillomavirus conference, Montreal 3-8 july 2010; (P669 and O456). Available at www.hpv2010.com (last accessed dec 2010).
10. th Biennial Meeting de la International Gynecologic Cancer Society. Prague, 23-26 October 2010; Available at http://www2.kenes.com/igcs-2010/pages/ home.aspx (last accessed dec 2010).
11. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines 2009; 5:696-704.
12. th International Papillomavirus conference, Montreal 3-8 july 2010; (O457). Available at www.hpv2010.com (last accessed dec 2010).
13. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; Epub 2010 Nov 8; PMID: 21067976R.
14. Palefsky JM. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010; 46:12-9.
15. th International Papillomavirus conference, Montreal 3-8 july 2010; (O508). Available at www.hpv2010.com (last accessed dec 2010).
16. Gross M, Andres R, Soren K. Human Papillomavirus (HPV) Vaccination and Pap Smears Results In Adolescent Girls - Have we seen a difference? J Pediatr Adolesc Gynecol 2010; 23; DOI: 10.1016/j.jpag.2010.01.022.
17. Information from FDA And CDC on the Safety of Gardasil Vaccine. Available at: http://www.fda.gov/BiologicsBloodVaccines /SafetyAvailability/ VaccineSafety/ucm179549.htm (last access dec 2010).
18. WHO position paper. Human papillomavirus vaccines. Wkly Epidemiol Rec 2009; 84:118-31.
19. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40.
20. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009; 27:7270-81.
21. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28:4731-7.
22. Bonanni P, Cohet C, Kjaer S, Latham NB, Lambert PH, Reisinger K, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010; 28:47:19-30.
23. Spanish Law on medicines 25/1990 of 20 of November. BOE 22 December of 1990; Avalilable at: www.boe.com (last access dec 2010).
24. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9. (Pubitemid 46843434)
25. Moscicki AB. Anamnestic response elicited by a fourth dose oh the HPV-16/18 AS04-adjuvanted vaccine in young women. SS11-6, presented at EUROGIN 2010; 17-20 of February (Monte Carlo).
26. Moscicki AB. Anamnestic response to non-vaccine types elicited by a fourth dose of the HPV- 16/18 AS04-adjuvanted vaccine. SS3-4, presented at EUROGIN 2010; 17-20 of February (Monte Carlo).
27. Ault K. Impact of quadrivalent HPV (type 6, 11, 16, 18) vaccine on HPV 18-related disease including adenocarcinoma of the cervix. Presented at EBCOG 2008; Lisbom (Portugal).
28. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71.
29. Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010; 5:19.
30. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie V. Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine. A Systematic Review. Pharmacoeconomics 2009; 27:127-47.
31. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. Vaccine 2009; 27:6060-79.
32. WHO position paper: Human papillomavirus vaccine. Biologicals 2009; 37:338-44.
33. Cain JM, Ngan H, Garland S, Wright T. For the FIGO Working Group on Combating Cervical Cancer: Control of cervical cancer: Women's options and rights. Int J Gynaecol Obstet 2009; 106:141-3.
34. Cortés Bordoy J, Martinón-Torres F. The Spanish human papillomavirus vaccine consensus group: A working model. Hum Vaccin 2010; 6.
35. Cortes Bordoy J. Women's attitudes and knowledge about HPV disease. Presented at EBCOG 2010; 5-7 of May (Amberes).
36. th International papilomavirus conference; Malm 2009.
37. Langeron N, Remy V, Oyee J, San-Martín M. [Cost-effectiveness analysis of HPV vaccine against 6, 11, 16 and 18 types in Spain]. Vacunas 2008; 9:3-11.
38. Yudin MH. HPV Vaccination: Time to End the Debate. J Ped Adolesc Gynecol 2010; 23:55-6.
39. Hoffner B. Vaccination against the Human Papillomavirus: the lessons we have not learned. Vaccine 2009; 27:2195-8.
40. Cortés J, Martinón-Torres F, Ramón y Cajal JM, Gil A, Velasco J, Avizanda M, et al. [Primary and secondary prevention of cancers of the cerviz and vulva: recommendations for clinical practice]. Prog Obstet Ginecol 2010; 53:1-19.